Cystic Fibrosis Therapeutics Market - Forecasts to 2026

As per the research conducted by GME, the Global Cystic Fibrosis Therapeutics Market will grow with a CAGR value of 13.5% by 2026. Cystic fibrosis is becoming more prevalent, resulting in increased awareness, technological improvements, strong pipeline prospects, and expanding R&D initiatives which are some of the factors to influence the growth of the market. The disease has no permanent cure but the symptoms and complications can be reduced by early diagnosis and proper treatment.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Cystic Fibrosis Therapeutics Market - Forecast to 2026” https://www.globalmarketestimates.com/market-report/global-cystic-fibrosis-therapeutics-market-3184

By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral drugs, Inhaled drugs), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
• Mucoviscidosis often referred to as cystic fibrosis, is a hereditary condition that is characterized by improper sodium and chloride transport through an epithelium, resulting in a lung infection that impairs breathing.
• CFTR Modulators are leading the market as per drug class and inhalation method as per route of administration
• One of the key factors expected to grow the market in the approaching years is increasing awareness among healthcare professionals and patients about advanced treatments in the APAC market
• Laurent Pharmaceuticals, Spyryx Biosciences, Zambon Pharmaceuticals, AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT - Advanced Inhalation Therapies; Alaxia; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; Alcresta Therapeutics, Inc.; Allergan, AstraZeneca, Translate Bio, Morphic Therapeutic, Galecto Biotech, and Lung Therapeutics among others are the top players in the cystic fibrosis therapeutics market

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-cystic-fibrosis-therapeutics-market-3184

Drug Class Outlook (Revenue, USD Billion, 2021-2026)
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators
• CFTR Modulators

Route of Administration Outlook (Revenue, USD Billion, 2021-2026)
• Oral drugs
• Inhaled drugs

Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
• The U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC
Central & South America
• Brazil
• Argentina
• Rest of CSA
Middle East & Africa
• Saudi Arabia
• UAE
• Rest of MEA

Contact: Yash Jain
Email address: yash.jain@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php

B-502, Kemp Plaza, Mindspace, Malad West, Mumbai: 400 064, India

Global Market Estimates is an India based market research and consulting company. The company provides syndicated research reports, customised research reports and consulting services to their clients and helps them achieve their business goals on a commercial level. Global Market Estimates database is used by the world's well known and prolific academic institutions and Fortune 500 companies to understand the global and regional business environment to excel in their business goals.

This release was published on openPR.